Details

INTRODUCTION<br> Development of the Private Equity and Venture Capital Market<br> Development of the Biotech Industry<br> METHODOLOGY<br> Formulating the Research Goal<br> Conducting the Study<br> Evaluating the Results<br> DATA ANALYSIS AND INTERPRETATION OF RESULTS<br> Description of Interview Partners<br> Major Characteristics of an Entrepreneur<br> Major Characteristics of a Venture Capitalist<br> The Most Important Partnering Criteria<br> Financing Models<br> Biotech Research Areas<br> Alliances and Funding in the Early Stage<br> Alliances and Funding in the Late Stage<br> Exit Routes<br> Primary Causes of Failure<br> Best-practice Countries for Funding Biotech Start-ups<br> Striking Differences between the US and European Venture Capital Markets<br> BIOTECH CASE STUDIES<br> AUSTRIANOVA Biomanufacturing AG<br> AVIR Green Hills Biotechnology AG<br> EUCODIS GmbH<br> Intercell AG<br> onepharm Research & Development GmbH<br> SUMMARY AND CONCLUSIONS<br> The Challenge: When Science Meets Business<br> Checklists<br> Final Observations<br> OUTLOOK AND RECOMMENDATIONS<br> EPILOGUE<br> REFERENCES<br> APPENDICES

"Gruber has become a veteran of marketing and business development in the pharmaceutical industry around the world, specializing in marketing and licensing biotechnological and generic products. She conducted qualitative interviews with entrepreneurs, venture capitalists, and other investors about the interpersonal and financial aspects of starting a biotech company, and presents the results here. By describing the characteristics beliefs, and expectations of each of the groups, she hopes to help investors and entrepreneurs build relationships based on mutual understanding that will lead to greater success in the biotech business, and most especially European companies in competition with American ones." (<i>SciTech Book News</i>, December 2010)<br /> <br />

Alexandra Carina Gruber, born in 1971 in Vienna, Austria, has been working in the pharmaceutical industry for the past 12 years, where she has held various marketing and business development positions and developed a profound expertise in the marketing and licensing of biotech and generic products. She is currently Director of Business Development & Marketing at BIOCRATES Life Sciences in Innsbruck Austria.

Based on interviews with dedicated biotech entrepreneurs and high-level investors as well as case studies, this title provides a comprehensive overview of current trends in biotech funding. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations. <p>The book outlines the various funding opportunities for the biotech industry in Europe and identifies ways for both sides to overcome their existing prejudices in order to successfully thrive in a competitive environment. A must-have for biotech entrepreneurs and investors, as well as invaluable supplementary reading for students aspiring to a career in the industry.</p>

DE